Ascend Montclair Pharmacy Launches Medical CBD SalesNote

Aug.22.2022
Ascend Montclair Pharmacy Launches Medical CBD SalesNote
Ascend Montclair pharmacy launched medical CBD last weekend, drawing in a steady crowd of customers.

Last Saturday, Ascend Montclair pharmacy launched medical CBD products during their weekend sale, attracting a steady stream of customers to the pharmacy.

 

Michele DeZao, a 60-year-old from Rockaway, was also among those who came to inspect. Two months ago, she obtained a medical CBD card and this was her second time visiting the pharmacy.

 

The cancer-disabled patient in recovery immediately noticed that the crowd on Saturday was increasing. However, she was relieved to have received priority treatment in the queue reserved only for medical patients to be discharged.

 

The hours between 8am to 10am are reserved exclusively for medical patients, while adult tobacco purchases begin at 10am every day of the week at Ascend Montclair.

 

I have no problem," Dezo said while paying, claiming it helps alleviate stomach pain. "Anyway, people are buying it (adult tobacco), so why not make it legal?

 

On August 20, 2022, Michele DeZao picked up her medical marijuana from Ascend Montclair pharmacy. The pharmacy, located at 395 Bloomfield Avenue, officially opened its doors on Friday at 10am and became the 19th pharmacy in New Jersey to sell adult-use cannabis after weeks of negotiations with the town. Alexandra Pais of NJ Advance Media captured the moment.

 

We appreciate the support of the Montclair community and are excited to share the Ascend experience with people in Montclair and surrounding towns," said Caitlin Fleishman, Public Affairs and Communications Director for Ascend Wellness, the multi-state operator of the pharmacy.

 

Last Tuesday, the Montclair Township administration voted 5-1 in favor of a pre-negotiated settlement agreement with Ascend, allowing for the sale of adult tobacco products.

 

Peter Yacobellis, the town consultant, stated that as part of the settlement agreement, Ascend Montclair will provide "voluntary donations" to various organizations using revenue from adult tobacco sales.

 

In an email, Yacobellis praised Ascend for their incredible generosity towards the citizens of Montclair, particularly their contributions to the Montclair Community Development Corporation and the Montclair Pre-K program. Yacobellis also emphasized the importance of ensuring that low-income and communities of color benefit from the revenue generated by the new cannabis market, as these communities have been disproportionately impacted by legacy marijuana laws.

 

The owner and co-founder of Ascend announced that another New Jersey location in Roselle Park launched adult tobacco sales statewide on April 21 and quickly became one of their top-performing adult cannabis stores in the U.S.

 

Ascend Fort Lee began selling medical marijuana on August 12th and plans to expand into adult CBD in the fall.

 

At Ascend Montclair, "there is a lot of traffic and support," said Fleishman.

 

Statement:

 

This article is compiled from third-party information and is intended solely for industry professionals for discussion and study purposes.

 

This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.

 

Due to limitations in translation ability, this article may not accurately reflect the meaning of the original text. Please refer to the original text for accuracy.

 

2FIRSTS is in full agreement with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or international issues and positions.

 

The compilation information is the property of the original media and author. If there is any infringement, please contact us for deletion.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07